Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07230834 · ClinicalTrials.gov registry record · Phase 1
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
A Phase 1 study of Geographic Atrophy (GA), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 4
- Study locations
NCT07230834 is a Phase 1 study of Geographic Atrophy (GA) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 54 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT07230834, a Phase 1 study of Geographic Atrophy (GA), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Pozelimab
Study Locations (4)
Texas
- Austin Retina Associates - Austin
- Retina Consultants Texas - The Woodlands
Colorado
- Colorado Retina Associates - Lakewood
Massachusetts
- Ophthalmic Consultants of Boston - East Weymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2026-01-19 |
| Est. Completion | 2028-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07230834
The ClinicalTrials.gov registry entry for NCT07230834 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy (GA) appearing as the primary indexed condition, and to 1 intervention - of which Pozelimab is the first listed.
NCT07230834 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07230834 about?
NCT07230834 is a clinical study titled "Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants". This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to ...
What is the current status of trial NCT07230834?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2026-01-19. Estimated completion is 2028-07-03.
What conditions does trial NCT07230834 study?
This clinical trial studies the following conditions: Geographic Atrophy (GA).
What interventions are being tested in trial NCT07230834?
The interventions under investigation include: Pozelimab (DRUG).
Who is sponsoring clinical trial NCT07230834?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07230834 being conducted?
This trial has 4 study locations across Colorado, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy (GA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.